Insulin-Glucose-Glucagon Network: Defining a Type 1 Diabetes Progression Index

Completed · Not applicable

Conditions studied: Diabetes Mellitus, Type 1

In brief

The type 1 Diabetes (T1D) TrialNet Pathway To Prevention (PTP) Study assesses and recruits at-risk subjects into clinical trials aimed at preventing the development of full blown T1D. Thousands of first and second degree relatives of persons with T1D are screened for autoimmune abnormalities and positive subjects are followed with metabolic and autoantibody tests. The investigators' ancillary study us designed to test whether characterization of the insulin- glucose-glucagon (IGG) interactions in participants in the PTP study can provide new information about the early stages of the disease. When completed, this study will improve the understanding of the pathogenesis of the early stages of T1D and provide new quantitative tools for prediction and evaluation of insulin-glucagon-glucose interactions relevant to individuals at risk for developing T1D, thereby enabling future preventive intervention trials.

Key facts

Study ID

NCT02663661

Run by

University of Virginia

People needed

73

Starts

2016-03-16

Expected to finish

2019-06-30

Last updated by the study team

2019-07-23

Who can join

Age: 12 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Individuals 12 to 45 years old which have a brother, sister, child, or parent with type 1 diabetes, or
• Individuals 12-20 years old who have have a cousin, aunt, uncle, niece, nephew, half-brother, half-sister, or grandparent with type 1 diabetes.

You may not qualify if…

• Have diabetes already (type 1 or type 2)
• Have a medical condition or being been treated with medications that might interfere with the study

Where it is running

• University of Virginia, Center for Diabetes Technology — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.